AEON Insider Trading

22.78% of AEON Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

AEON Biopharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/14/2024	Davidson Kempner Capital Management LP	90,053	$95K	0.0%	-75.4%	0.230%
5/17/2024	Shaolin Capital Management LLC	21,380	$0.25M	0.0%	-97.7%	0.057%
5/10/2024	Vanguard Group Inc.	758,992	$8.80M	0.0%	+261.8%	2.008%
2/7/2024	Formidable Asset Management LLC	58,193	$0.42M	0.1%	-9.5%	0.157%
11/9/2023	Formidable Asset Management LLC	64,311	$0.36M	0.1%	N/A	0.723%
11/6/2023	Atalaya Capital Management LP	3,675,000	$19.83M	21.7%	N/A	41.283%

Data available starting January 2016

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Today's Range

Now: $1.01

$1.00

$1.03

50 Day Range

MA: $0.94

$0.67

$1.50

52 Week Range

Now: $1.01

$0.64

$17.17

Volume

45,883 shs

Average Volume

591,179 shs

Market Capitalization

$39.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Who are the company insiders with the largest holdings of AEON Biopharma?: AEON Biopharma's top insider shareholders include:
Crown Holdings Grou Strathspey (Major Shareholder)
Learn More about top insider investors at AEON Biopharma.